ABSTRAm. Carnitine plasma concentrations and the ex-(I) and regenerating intramitochondrial coenzyme A through cretion of carnitine and individual carnitine esters were transport of acyl-groups out of the mitochondria, thereby maindetermined in 25 children and adolescents with gastroin-taining conditions required for oxidative processes (2). testinal diseases receiving carnitine-free parenteral nutriAlthough carnitine is synthesized de novo in mammalian tion for at least 1 mo using radiochemical and radioisotopic tissues (3). nutritional carnitine deficiency may occur under exchange HPLC methods. Children ~12-y-old usually had certain circumstances if carnitine is not provided with the diet. carnitine plasma concentrations C-2 SD from the normal Infants receiving carnitine-free TPN are particularly prone to mean for age, whereas patients >12-y-old had carnitine develop carnitine deficiency, probably due to impaired carnitine plasma concentrations within the normal range. Age was biosynthesis (4) and low carnitine tissue stores (5). Moreover, the only variable to correlate significantly with plasma infants on TPN appear to have a decreased capacity to oxidize carnitine concentrations during parenteral nutrition. Free fatty acids that can be improved by L-carnitine supplementation carnitine (FC) excretion was closely correlated with plasma (6, 7). The question has therefore been raised whether carnitine FC concentrations and minimal at values <25 rmol/L. The should be considered an essential nutrient for the infant (8). excretion of FC and short-chain acylcarnitines was reduced It is not known at what time during human development by an order of magnitude in younger compared with older endogenous carnitine biosynthesis becomes adequate. Adults patients and controls, but the excretion of "other" acylcar-receiving TPN maintain a normal carnitine status over a longer nitines was less affected. Some of the latter were tentatively period of time than infants (9). Nonetheless. abnormally low identified using gas-liquid chromatographic and mass spec-carnitine plasma concentrations were found in 35% of an adult troscopic techniques as unsaturated and/or branched me-population on long-term home PN (10). Some of them also had dium-chain carnitine esters with a carbon chain of C8-decreased liver carnitine content. The pathogenesis of this is not C10. The results suggest that FC and short-chain acylcar-understood because, in the mature individual, endogenous carnitine are conserved by the kidney in nutritional carnitine nitine biosynthesis should be adequate if precursors are provided deficiency but that there may be an obligatory renal excre-with TPN. However, loss of carnitine through the kidney may tion of other carnitine esters that contributes to the devel-be an important factor. opment of hypocarnitinemia in the younger age group.
ABSTRAm. Carnitine plasma concentrations and the ex-(I) and regenerating intramitochondrial coenzyme A through cretion of carnitine and individual carnitine esters were transport of acyl-groups out of the mitochondria, thereby maindetermined in 25 children and adolescents with gastroin-taining conditions required for oxidative processes (2) . testinal diseases receiving carnitine-free parenteral nutriAlthough carnitine is synthesized de novo in mammalian tion for at least 1 mo using radiochemical and radioisotopic tissues (3) . nutritional carnitine deficiency may occur under exchange HPLC methods. Children ~12-y-old usually had certain circumstances if carnitine is not provided with the diet. carnitine plasma concentrations C-2 SD from the normal Infants receiving carnitine-free TPN are particularly prone to mean for age, whereas patients >12-y-old had carnitine develop carnitine deficiency, probably due to impaired carnitine plasma concentrations within the normal range. Age was biosynthesis (4) and low carnitine tissue stores (5) . Moreover, the only variable to correlate significantly with plasma infants on TPN appear to have a decreased capacity to oxidize carnitine concentrations during parenteral nutrition. Free fatty acids that can be improved by L-carnitine supplementation carnitine (FC) excretion was closely correlated with plasma (6, 7) . The question has therefore been raised whether carnitine FC concentrations and minimal at values <25 rmol/L. The should be considered an essential nutrient for the infant (8) . excretion of FC and short-chain acylcarnitines was reduced It is not known at what time during human development by an order of magnitude in younger compared with older endogenous carnitine biosynthesis becomes adequate. Adults patients and controls, but the excretion of "other" acylcar-receiving TPN maintain a normal carnitine status over a longer nitines was less affected. Some of the latter were tentatively period of time than infants (9) . Nonetheless. abnormally low identified using gas-liquid chromatographic and mass spec-carnitine plasma concentrations were found in 35% of an adult troscopic techniques as unsaturated and/or branched me-population on long-term home PN (10) . Some of them also had dium-chain carnitine esters with a carbon chain of C8-decreased liver carnitine content. The pathogenesis of this is not C10. The results suggest that FC and short-chain acylcar-understood because, in the mature individual, endogenous carnitine are conserved by the kidney in nutritional carnitine nitine biosynthesis should be adequate if precursors are provided deficiency but that there may be an obligatory renal excre-with TPN. However, loss of carnitine through the kidney may tion of other carnitine esters that contributes to the devel-be an important factor. opment of hypocarnitinemia in the younger age group.
FC and/or AC excretion has been shown to be increased during (Pediatr Res 28: 158-165,1990) TPN in adult patients with multiple injuries (I I), with sepsis, and after surgery (12) , but decreased in metabolically stable Abbreviations patients receiving long-term PN (13). Individual carnitine esters were not analyzed in the urine of these patients. PN, parenteral nutrition It has been suggested that carnitine plays a role in mitochon-TPN, total parenteral nutrition drial detoxification of excess or slowly metabolized coenzyme A-FC, free carnitine linked compounds of endogenous or exogenous origin (14) . TC, total carnitine These acyl moieties are eventually excreted in the urine as AC.
AC, acylcarnitine
This has been well documented in inborn errors of organic acid SCAC, short-chain acylcarnitine metabolism. We hypothesized that such a mechanism may be MCAC, medium-chain acylcarnitine operational even in metabolically normal humans. The associ-PEG, polyethylene glycol ated carnitine loss may lead to decreased carnitine concentrations IBD, inflammatory bowel disease in susceptible individuals if carnitine is not provided with nutrition.
In the following, we report the carnitine status and excretion of carnitine and carnitine esters in children and adolescents with gastrointestinal diseases requiring PN for at least 1 mo using a Carnitine (~-hydroxy-y-trimethylamino-butyric acid) plays an radioisotopic exchange HPLC method recently adapted for huimportant role in energy metabolism by facilitating the transport man urine (1 5). In addition, L-carnitine absorption was studied of FFA across the inner mitochondria1 membrane for P-oxidation in a child with a functional short bowel. plasma TC as the dependent variable and age, duration of PN, and oral intake as the independent variables. carnitine concentrations could be measured before the onset of PN (Fig. 2 ). Of the group 1 patients, two (nos. 9 and 14) had decreased and two (nos. 5 and 6) had normal carnitine plasma concentrations at that time. All were malnourished with wt/ht < 3rd percentile and hypoalbuminemia. All six patients of group 2 had normal carnitine plasma concentrations before the onset of PN. Four of them were also malnourished. In eight of 10 patients, carnitine plasma concentrations dropped after 1 mo of PN. They remained relatively constant thereafter in those patients who were followed for up to 4 mo (Fig. 2) . Carnitine excretion. Because of exceptionally low carnitine concentrations in plasma and urine, patient no. 16 . who had massive blood loss from his colon requiring several transfusions of red blood cells, was excluded from the statistical evaluation of the carnitine excretion data. Urinary excretion of TC, FC, and AC was lower and the percentage of TC excreted as AC was higher in group 1 compared with group 2 patients or control children (Table 3 ). Carnitine excretion was not different between patients in groups 2 and 3.
RESULTS

Plasma carnirine. TC, FC, and AC plasma concentrations
were lower in patients in group 1 than in those in group 2 ( Table  2) . Differences in TC and FC plasma concentrations between groups 2 and 3 were much less pronounced. All children except one (no. 1 1) of group 1 had TC plasma concentrations <-2 SD from the normal mean for age (16) . With one exception (no. 16), all patients in group 2 had TC and FC plasma concentrations within 2 SD of the normal mean for age.
Among the variables tested by multiple regression analysis, only age was significantly correlated with TC plasma concentrations (expressed as % of the normal mean, r = 0.68, p < 0.001, Fig. 1 ). This correlation was still significant even if only patients in group 1 were considered ( r = 0.52, p < 0.05).
In 10 children (four in group 1 and six in group 2), plasma 
AGE (months)
Fig. 1. Relationship hetween TC plasma concentrations (expressed as % of the normal mean for age) and age of 25 children and adolescents receiving PN for >I mo. y = 36.00 + 0.19x. r = 0.68. p < 0.001.
As shown in Figure 3 , there was a positive correlation ( r = 0.80. p < 0.001) between plasma FC concentrations and FC excretion (expressed as nmo1/100 mL glomerular filtrate). At FC plasma concentrations of <25 pmol/L. FC excretion was minimal. The two patients with renal Fanconi syndrome had a high excretion of FC despite low FC plasma concentrations. The mean fractional tubular reabsorption of FC was 99.7% in group 1, 96.8% in group 2, and 97.1 % in group 3 patients. The difference between groups 1 and 2 was significant ( p < 0.015), indicating the ability to conserve FC in the former.
The urinary excretion of all SCAC and other AC was lower in group I than in group 2 or controls (Tables 4 and 5 ). However, the differences were more pronounced for SCAC (-10-fold) than for other AC (2-to 3-fold). The percentage of TC excreted as SCAC was lower and that excreted as other AC higher in group 1 compared with group 2 or controls (Table 5 ). Carnitine ester excretion was not different between patients in groups 2 and 3.
Identity of carnitine esters. Figure 4 shows HPLC chromatograms of urinary carnitine esters of patient no. 1 1 of group 1 and no. 18 of group 2. In the former (Fig. 4A) , peaks in the area of MCAC were more pronounced relative to SCAC peaks (C-2 to C-5) than in the latter (Fig. 4B) . In the urine of patient no. 11, the prominent peak C-4 (retention time, 20.1 min) was identified as isobutyrylcarnitine ( Table  6 ). The MCAC in the urine of patient no. 1 I and a control child were (partially) identified as shown in Table 6 and Figures 5 and 6. Due to limited amounts of material, only the structure of the compound with a retention time of 36.8 min on HPLC could be established as 2-methyloctanoylcarnitine. This peak was found in the urine of 60% of the control children, in all patients in group 3, and only occasionally in patients receiving PN (groups 1 and 2). The peaks with retention times of 33.7 and 35.3 min on HPLC were found in practically all urine samples studied. No octanoylcarnitine (retention time 36.1 min) was present in any specimen.
Carnitineahsorption study. Absorption of L-carnitine was studied in patient no. 7, who had a jejunostomy. His TC and FC plasma concentrations were 20.4 and 18.0 rmol/L. respectively. age was the only variable to correlate significantly with plasma TC concentrations (expressed as % of normal mean for age) in our patients receiving >1 mo of carnitine-free PN suggests that the rate of endogenous carnitine biosynthesis and/or carnitine tissue reserves are insufficient in very young patients to meet carnitine requirements during rapid growth. This is supported by the study of Helms et al. (7) , in which young infants (mean age 3 mo) receiving long-term PN had even lower TC plasma concentrations (mean 9 pmol/L) than our patients in group I .
On the other hand, the type of disease was strikingly different between our two patient groups. Extensive small bowel disease resulting in diarrhea and malabsorption (group 1) may have led to decreased carnitine reserves even before the onset of PN due to impaired intestinal absorption of carnitine or its precursors. This is supported by the finding of abnormally low plasma carnitine concentrations before initiation of PN in two of the four longitudinally studied patients with malabsorption. Moreover, we recently found carnitine plasma concentrations to be <-1 SD from the normal mean for age in four of five children with total villous atrophy due to celiac disease (Hebel E and Schmidt-Sommerfeld E, unpublished data). Carnitine absorption has not been studied in vivo in the human, but it has been shown to be a sodium-dependent active process in biopsy specimens from duodenum and ileum (27). Our absorption study in a child with jejunostomy demonstrates that carnitine absorption can be severely impaired in a patient with a short small intestine.
In two children in group 1, we were able to observe carnitine plasma concentrations over a period of 3-4 mo of PN. In both children, levels dropped after 1 mo to subnormal values and then remained unchanged. This suggests that plasma carnitine concentrations attain a new steady state at a decreased level during carnitine-free nutrition.
Most of our children and adolescents >I2 y of age with IBD maintained plasma carnitine concentrations in the normal range. Moreover, plasma carnitine concentrations differed only slightly from those in age-matched IBD patients not receiving PN. This indicates that, in this patient population, carnitine reserves and synthetic capacity are probably adequate to maintain a normal carnitine status over an extended period of time on PN (mean 10 mo). This finding is at variance with a study that reported that 35% of adult patients with gastrointestinal disease receiving home PN had decreased carnitine plasma concentrations (10) . However, these patients were on PN for a longer period of time (mean 32 mo) and most of them, in contrast to our patients in group 2, had short bowel syndrome.
Carnitine excretion was markedly different between our two Plasma FC (pmolesll) Fig. 3 . Relationship between FC plasma concentrations and FC excretion (expressed as nmo1/100 mL glomerular filtrate). El, patients receiving PN (groups I + 2): U, patients with IBD on oral food (group 3): +. two patients with renal Fanconi syndrome receiving PN (not included in the statistical evaluation).
Carnitine concentration was minimal (<2 pmol/L) in the initial ostomy output. Four h after L-carnitine and D-xylose administration, all of the administered carnitine was recovered from the ostomy and plasma carnitine concentrations were unchanged. Twelve percent of the administered D-xylose was absorbed and the 1-h D-xylose blood level was 8 pg/dL.
DISCUSSION
In the human, there is indirect evidence that low plasma carnitine concentrations reflect decreased carnitine tissue levels, at least in organs with a relatively high turnover rate for carnitine. Premature infants receiving carnitine-free TPN have decreased carnitine concentrations not only in plasma (25, 26), but also in liver, heart, and kidney (5). It has therefore been suggested that infants may have impaired endogenous carnitine biosynthesis. However, it is not known at what age the capacity for carnitine biosynthesis is fully developed in the human. Our finding that Table 4 . Urinary excretion (~rnollg creatinine) of short-chain carnitine esters* n Acetyl-carnitine Propionyl-carnitine Isobutyryl-carnitine C5-acyl-carnitine
The groups are the same as in Table 3 . 1, median; R, range; R, t p < 0.001 compared with group 2. S p < 0.001 compared with controls.
3 p < 0.02 compared with group 2.
11 p < 0.003 compared with controls.
mean. Table 5 . Urinary e,~crerion of SCAC and other carnirine ester.7 11 p < 0.003 compared with controls. t Fast atom bombardment mass spectrometry.
i Previouslv identified in adult urine (22. 38).
5 Gas-liquid chromatography electron impact mass spectrometry of the acyl moiety. Figure  4A with retention times of 33.7 ( A ) and 35.3 (R) min. A : Protonated mol wt = 286 (Na-adduct mol wt = 308) best fit an 8-carbon AC with one double bond. B: Protonated mol wt = 330 (Na-adduct mol wt = 352) best fit a 10-carbon AC with an OH-group and one double bond: protonated mol wt = 310 best fits a 10-carbon AC with three double bonds (see Table 6 ). Peaks at 207.277.299. 369. and 39 1 are due to the glycerol matrix used.
groups of patients receiving PN, but not different between groups 2 and 3 (IBD with and without PN). This suggests that carnitine excretion is not influenced by the type of nutrition or carnitine intake, but primarily by plasma carnitine concentrations. The Table 6 ). B. Gas-liquid chromatographic electron impact mass spectral analysis of the acyl moiety after hydrolysis: base peak 74 and fragment 87 indicate a methyl branch in position 2. apparent renal threshold for FC was -25 pmol/L in our patient population. This value is lower than the extrapolated value (46 pmol/L) reported by Engel ef al. (28) in normal adults receiving i.v. L-carnitine. Because all our children with low FC blood concentrations and low urinary FC excretion received PN and were in the younger age group, we cannot comment as to whether the apparent renal threshold for FC is influenced by PN or age. Although the kidney was capable of conserving FC when plasma levels were decreased, FC was always detected in the urine. This may reflect secretion of FC by the kidney (29) .
Quantitation of individual urinary carnitine esters revealed that the excretion of short (branched)-chain AC was also sharply reduced in our patients in group 1, suggesting that they are reabsorbed by the kidney tubule to a similar extent as FC. This is in agreement with studies by Hokland and Bremer (30) using the perfused rat kidney. However, the excretion of other carnitine metabolites including MCAC was reduced to a much lesser extent in group I patients and was appreciable in all patient groups and controls. These AC made up a significantly higher percentage of TC excreted by patients in group 1 compared with group 2 or age-matched controls.
We were able to identify tentatively some of these compounds as unsaturated and/or branched medium-chain carnitine esters with a carbon chain of C-8 to C-10. Kerner ef al. (22) have previously identified three medium-chain carnitine esters in urine from adults as 2-methyl-Ah-octenoyl-, Ah-octenoyl-, and 2-methyloctanoylcarnitine. The latter two compounds are probably identical to those found in our children.
The origin of these medium-chain carnitine esters, which are distinctly different from octanoyl-and hexanoylcarnitine excreted by patients with medium-chain acyl-CoA dehydrogenase deficiency (3 I), is unknown. They could be derived from exogenous or endogenous fats. The finding that some of them were excreted in all of our subjects independent ofthe type of nutrition they received suggests that an endogenous origin is likely. This is supported by our recent finding of complex medium-chain carnitine esters in the urine of newborn infants collected before the onset of feedings (Schmidt-Sommerfeld E, unpublished data). It is also not known in which organs and cell organelles they are formed and whether they are transported through the blood stream. Nor is it known which carnitine acyltransferases are involved in their formation. Some of them may be secreted directly into urine by the kidney. Hokland and Bremer (30) found unidentified carnitine metabolites in rat urine after perfusion of the kidney with labeled carnitine. Judging from their Rr values on thin-layer chromatography, these metabolites could have been medium-chain carnitine esters.
It has been suggested that, in renal Fanconi syndrome (32, 33) , organic acidurias (34) , and primary disturbances of carnitine transport (35), carnitine deficiency results from carnitine loss in the urine. Apart from our two patients with renal Fanconi syndrome, this was not apparent in our hypocarnitinemic patients in group l . Their kidneys were able to conserve FC and SCAC. However, they lost appreciable amounts of carnitine in the form of MCAC and other yet to be identified carnitine esters with the urine.
On the basis of these findings, one could speculate that carnitine has a role in the removal of presumably slowly metabolized acyl moieties from the body. Such a role has been suggested before for the elimination of fatty acid-like drugs such as valproic and pivaloic acids, which are excreted as their respective carnitine esters (36, 37). This normal metabolic pathway proceeds despite hypocarnitinemia and contributes to a state of carnitine deficiency in young children who receive carnitine-free nutrition and in whom rates of endogenous carnitine biosynthesis may be inadequate. It remains to be established whether carnitine supplementation of PN is warranted in this situation.
